Study to Evaluate the Pharmacokinetics (movement of drugs within the body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants

Exclusion Criteria

• • History of any clinically significant disease or disorder in any body system
• • Clinical signs and symptoms consistent with Coronavirus disease 2019 (COVID-19), eg, fever, dry cough, dyspnoea, sore throat, fatigue, or confirmed infection by appropriate laboratory test within the last 4 weeks prior to the Screening period or on admission
• • History of alcohol or other substance abuse within the previous 5 years
• • Known hypersensitivity to biologic therapy
• • Taken any concomitant medications (including over-the-counter medications such as aspirin, acetaminophen, ibuprofen, herbal [including traditional Chinese medicinal products] or dietary supplements and cough syrup, as well as medicines requiring a prescription) within 14 days or 5 half-lives (whichever is longer), or St John's Wort within 30 days before the study drug administration
• • Previously taken brazikumab or previously participated in an investigational study of brazikumab (previously known as AMG139 or MEDI2070)
• • Participation in any other clinical investigation using an experimental drug within 30 days or 5 half-lives whichever is longer prior to dosing on Day 1
• • For study participants for whom the COVID-19 vaccination is planned, vaccination (all doses) prior to first study drug dose may be advisable. If possible, the first dose of brazikumab should be given at least 30 days after the last dose of vaccine
• • Blood or plasma donation within 60 or 30 days, prior to dosing on Day 1
• • Any clinically significant abnormal findings in vital signs at the Screening period
• • Abnormal electrocardiogram results thought to be clinically significant
• • Abnormal and clinically significant results on physical examination, medical history, serum chemistry, haematology, or urinalysis
• • Positive test results for anti-human immunodeficiency virus type 1 and type 2 antibodies, hepatitis B surface antigen and hepatitis B core antibody, anti-hepatitis C virus antibodies, human T-lymphotropic virus type 1 and human T-lymphotropic virus type 2 or tuberculosis at the Screening period
• • Consumption of alcohol within 72 hours before administration of the study drug
• • Positive test results for drug of abuse during the Screening period or on Day -1
• • The participant has a condition or is in a situation which, in the Investigator’s opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant’s participation in the study
• • Directly or indirectly involved in the conduct and administration of this study as an Investigator, Sub-investigator, study coordinator, or other study staff member; or employee of the Sponsor, or a first-degree family member, significant other, or relative residing with one of the above persons involved directly or indirectly in the study
• • Female participant who is breastfeeding
• • Evidence of a recent (within 6 months of Day 1) systemic fungal infection, requiring inpatient hospitalisation, and/or antifungal treatment
• • Any infection requiring hospitalisation or treatment with IV anti-infectives (including anti-viral treatment) within 4 weeks prior to Screening
• • Participant received a Bacille Calmette-Guérin vaccination within 12 months of Day 1 or any other live vaccine less than 4 weeks prior to Day 1 or is planning to receive any such vaccine over the course of the study
• • Judgement by the Investigator that the participant should not participate in the study if they have any ongoing or recent (ie, during the Screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements
• • Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order
• • Participants who cannot communicate reliably with the Investigator
• Detailed inclusion/exclusion criteria are in the study protocol